CTLA4 and cancer: In cases where the symptoms are moderate to severe, there may be significant morbidity and impairment of the nutritional and volume status, which may necessitate hospitalization and affect the patient’s eligibility to receive further cancer treatment.20 The use of ICIs (CTLA-4 and PD-1 inhibitors) was linked to a higher risk of both all-grade and high-grade colitis, according to a previously published meta-analysis.